Hikma Pharmaceuticals PLC engages in the development, manufacture, and marketing of generic and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates primarily in the United States, Europe, the Middle East, and North Africa. Segments The company operates in three segments: Branded Pharmaceuticals, Generic Pharmaceuticals, and Injectable Pharmaceuticals. Branded The Branded Pharmaceuticals segment develops, manufactures, and markets 241 solid, semi-solid, and liquid branded pharmaceutical products in 460 dosage strengths and forms, including 33 patented products under-license from the originator. Generics The Generic Pharmaceuticals segment develops, manufactures, and markets 47 non-branded generic pharmaceutical products in 105 dosage strengths and forms. Injectables The Injectable Pharmaceuticals segment develops, manufactures, and markets 81 injectable products in 202 dosage strengths and forms with a focus on anti-infectives, oncology, central nervous system, and cardiology areas. History Hikma Pharmaceuticals PLC was founded in 1978.
hikma pharmaceuticals plc
(HIK:London Stock Exchange)
13 Hanover Square
London, W1S 1HW
Phone: 44 20 7399 2760
Fax: 44 20 7399 2761www.hikma.com
|Actelion Ltd||SFr.120.30 CHF||-2.20|
|Akorn Inc||$29.84 USD||+1.62|
|Impax Laboratories Inc||$38.20 USD||+1.91|
|Pfizer Ltd/India||2,459 INR||+33.90|
|Medicines Co/The||$39.02 USD||+0.56|
|View Industry Companies|
Sponsored Financial Commentaries
To contact HIKMA PHARMACEUTICALS PLC, please visit www.hikma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.